Drug intelligence / Profile preview

bmd-3151

Development stage: Preclinical
Lead developer: BiologicsMD
Modality: Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes

Overview

BMD-3151 is a fusion protein drug acting as a parathyroid hormone receptor (PTH1R) antagonist. It is being developed for the treatment of bone metastases, primarily in the context of neoplasms. The drug was initially developed by the University of Arkansas System and is currently under preclinical development by BiologicsMD[1][4]. Its mechanism involves antagonizing PTH1R to potentially modulate bone metabolism and reduce complications associated with metastatic bone disease.

Targets

PTH1R (Parathyroid hormone/Parathyroid hormone-related peptide receptor type 1)COL1 (Collagen type I)

Beyond the preview

Go deeper on bmd-3151.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on bmd-3151.

Explore the full profile